Search Results for "Ovarian Cancer Prognostic Markers"
Original Source: Evaluating markers for treatment selection based on survival time.
For many medical conditions, several treatment options may be available for treating patients. We consider evaluating markers based on a simple treatment selection policy that incorporates information on the patient's marker value. For example, colon cancer patients may be treated by surgery alone or surgery plus chemotherapy. The c-myc gene expression level may be used as a biomarker for treatment selection. Although traditional regression methods may assess the effect of the marker and treatment on outcom...
Matching Channels
Tumor markers are substances produced by tumor cells or by other cells of the body in response to cancer or certain benign (noncancerous) conditions. These substances can be found in the blood, in t...
Ovarian cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women. Women at risk of Ovarian cancer are those who have had fe...
UGenRA - Genitourinary cancer array
UGenRA is a CGI custom-designed oligonucleotide array designed to detect gains and losses of genomic material in endometrial, ovarian, and cervical cancers. Endometrial hyperplasia is a precursor le...
Epithelial cell adhesion molecule EpCAM CD326
Epithelial cell adhesion molecule (EpCAM; CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian,...
Matching News
Team finds markers related to ovarian cancer survival, recurrence
Researchers at the University of Illinois have identified biomarkers that can be used to determine ovarian cancer survival and recurrence, and have shown how these biomarkers interact with each other...
Study investigates molecular markers in drug-resistant ovarian cancer
A new study by TCD researchers investigates drug-resistant ovarian cancer cells. The findings which have been recently published in the international publication, PLoS One will increase understanding...
Diagnosis: Novel prognostic biomarkers in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a heterogeneous cancer with variable outcomes after treatment. Prognosis of HCC cannot be accurately predicted by current clinical staging systems. Development of pro...
Prognostic Markers in Soft Tissue Sarcomas
This study examined the prognostic role of the innate immune system in soft tissue sarcomas by assessing the expression of a variety of growth factors and cellular markers. BMC Clinical Pathology
Genetic Markers for Ovarian Cancer Risk
What is the latest research on genetic testing for ovarian cancer risk? Personalized Medicine
UNM Cancer Center researcher looks for genetic markers for ovarian cancer
(University of New Mexico Cancer Center) Dr. Linda Cook recently won a four-year NCI grant to study the mitochondrial DNA differences in over 4,200 Canadian women with and without ovarian cancer. Usin...
CAF profiles could provide prognostic information beyond that of standard clinical classification and identify markers predictive of pazopanib benefit in patients with metastatic renal-cell carcinoma....
Big data analysis identifies prognostic RNA markers in a common form of breast cancer
(Ohio State University Medical Center) An analysis that integrates three large sets of genomic data available through The Cancer Genome Atlas has identified 37 RNA molecules that might predict surviva...
Matching PubMed Articles
Preoperative serum albumin is an independent prognostic predictor of survival in ovarian cancer.
Ovarian cancer is associated with high mortality due to asymptomatic nature of the disease and advance stage at presentation. In advanced stages, it is associated with cachexia and ascites leading to...
Abstract High tumor tissue mRNA expression of either the tumor biological factors uPAR, uPARdel4/ 5, or rab31, is associated with shorter distant metastasis-free and overall survival in breast cancer...
INTRODUCTION: Ovarian cancer is a gynecologic cancer with a high mortality rate, demonstrating the need for effective and reliable tumor markers during the staging and treatment processes. METHODS: Ex...
Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.
Malignant ascites presents a considerable clinical challenge to the management of ovarian cancer, but also provides a wealth of opportunities for translational research. The accessibility of ascitic f...
Cell-free DNA Level as a Prognostic Biomarker for Epithelial Ovarian Cancer.
The use of cell-free DNA (cfDNA) as a non-invasive biomarker has been evaluated in many types of cancer. This study investigated the prognostic significance of cfDNA level for ovarian cancer.
